MCID: PLY187
MIFTS: 36

Polyarticular Juvenile Idiopathic Arthritis

Categories: Bone diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Polyarticular Juvenile Idiopathic Arthritis

MalaCards integrated aliases for Polyarticular Juvenile Idiopathic Arthritis:

Name: Polyarticular Juvenile Idiopathic Arthritis 59 17
Juvenile Polyarthritis 59 33
Juvenile Polyarticular Arthritis 59
Polyarticular Jia 59

Classifications:



External Ids:

ICD10 33 M08.3
UMLS via Orphanet 73 C0409667
Orphanet 59 ORPHA404580

Summaries for Polyarticular Juvenile Idiopathic Arthritis

MalaCards based summary : Polyarticular Juvenile Idiopathic Arthritis, also known as juvenile polyarthritis, is related to rheumatoid factor-positive polyarticular juvenile idiopathic arthritis and arteritis, familial granulomatous, with juvenile polyarthritis. An important gene associated with Polyarticular Juvenile Idiopathic Arthritis is BTK (Bruton Tyrosine Kinase), and among its related pathways/superpathways are Diseases associated with the TLR signaling cascade and Toxoplasmosis. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and neutrophil, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Polyarticular Juvenile Idiopathic Arthritis

Diseases in the Polyarticular Juvenile Idiopathic Arthritis family:

Polyarticular Onset Juvenile Idiopathic Arthritis

Diseases related to Polyarticular Juvenile Idiopathic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 rheumatoid factor-positive polyarticular juvenile idiopathic arthritis 12.9
2 arteritis, familial granulomatous, with juvenile polyarthritis 12.4
3 juvenile rheumatoid arthritis 12.1
4 multicentric carpotarsal osteolysis syndrome 11.6
5 polyarticular onset juvenile idiopathic arthritis 11.5
6 arthritis 10.6
7 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 10.5
8 rheumatoid factor-negative juvenile idiopathic arthritis with anti-nuclear antibodies 10.5
9 rheumatoid factor-negative juvenile idiopathic arthritis 10.5
10 rheumatic disease 10.4
11 autoimmune disease 10.3
12 agammaglobulinemia, x-linked 10.3
13 uveitis 10.3
14 enthesopathy 10.3
15 agammaglobulinemia 10.3
16 macrophage activation syndrome 10.3
17 aortic valve insufficiency 10.2
18 enthesitis-related juvenile idiopathic arthritis 10.2
19 torticollis 10.1
20 multicentric osteolysis, nodulosis, and arthropathy 10.1
21 non-alcoholic fatty liver disease 10.1
22 nasopharyngitis 10.1
23 ventricular septal defect 10.1
24 heart septal defect 10.1
25 ankylosis 10.1
26 arthropathy 10.1
27 pustulosis of palm and sole 10.1
28 fibromyalgia 10.1
29 double outlet right ventricle 10.1
30 crohn's disease 10.1
31 psoriasis 10.1
32 fatty liver disease 10.1
33 47,xyy 10.1
34 anterior uveitis 10.1
35 aortic coarctation 10.1
36 spondylarthropathy 10.1
37 systemic onset juvenile idiopathic arthritis 10.1
38 hematopoietic stem cell transplantation 10.1
39 oligoarticular juvenile idiopathic arthritis 10.1
40 rheumatoid arthritis 10.0
41 poliomyelitis 9.8 TNF BTK
42 common variable immunodeficiency 9.8 TNF BTK
43 endocarditis 9.8
44 hemopericardium 9.8
45 mitral valve insufficiency 9.8
46 pericardial effusion 9.8
47 endomyocardial fibrosis 9.8
48 pericarditis 9.8
49 calcinosis 9.8
50 cataract 9.8

Graphical network of the top 20 diseases related to Polyarticular Juvenile Idiopathic Arthritis:



Diseases related to Polyarticular Juvenile Idiopathic Arthritis

Symptoms & Phenotypes for Polyarticular Juvenile Idiopathic Arthritis

GenomeRNAi Phenotypes related to Polyarticular Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 8.92 BTK CNR2
2 Decreased substrate adherent cell growth GR00193-A-2 8.92 CNR2
3 Decreased substrate adherent cell growth GR00193-A-4 8.92 BTK

Drugs & Therapeutics for Polyarticular Juvenile Idiopathic Arthritis

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Etanercept Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis. DB00005
2 Tocilizumab Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older. DB06273

Drugs for Polyarticular Juvenile Idiopathic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
3
Sulfasalazine Approved Phase 3 599-79-1 5359476 5353980
4
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
5
Hydroxychloroquine Approved Phase 3 118-42-3 3652
6
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
7
Ethanol Approved Phase 3 64-17-5 702
8
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
9
Infliximab Approved Phase 3 170277-31-3
10
Etanercept Approved, Investigational Phase 3 185243-69-0
11
Adalimumab Approved Phase 3 331731-18-1 16219006
12
tannic acid Approved Phase 3 1401-55-4
13
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
14
Abatacept Approved Phase 3 332348-12-6 10237
15
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
16
leucovorin Approved Phase 3 58-05-9 143 6006
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
19 Narcotics Phase 3
20 Narcotic Antagonists Phase 3
21 Prednisolone acetate Phase 3
22 Methylprednisolone Acetate Phase 3
23 Pharmaceutical Solutions Phase 3
24 Gastrointestinal Agents Phase 3
25 Rheumatoid Factor Phase 3
26 Analgesics Phase 3
27 Analgesics, Non-Narcotic Phase 3
28 Anti-Inflammatory Agents, Non-Steroidal Phase 3
29 Peripheral Nervous System Agents Phase 3
30 Anti-Inflammatory Agents Phase 3
31 Immunosuppressive Agents Phase 3
32 Antirheumatic Agents Phase 3
33 Immunologic Factors Phase 3
34 Folic Acid Antagonists Phase 3
35 Folate Phase 3
36 Vitamin B9 Phase 3
37 Nucleic Acid Synthesis Inhibitors Phase 3
38 Vitamin B Complex Phase 3
39 Dermatologic Agents Phase 3
40 Antimetabolites Phase 3
41 Antimetabolites, Antineoplastic Phase 3
42 Antibodies Phase 3
43 Antibodies, Monoclonal Phase 3
44 Immunoglobulins Phase 3

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA Completed NCT00792233 Phase 4
2 Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial. Completed NCT01015547 Phase 3 Infliximab plus methotrexate;Combination of DMARDs;Methotrexate alone
3 An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP Completed NCT00144625 Phase 3 MRA(Tocilizumab)
4 Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA) Completed NCT00775437 Phase 3 Adalimumab
5 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Completed NCT00048542 Phase 3 OLE BSA Adalimumab +/- MTX;OLE FD Adalimumab +/- MTX
6 Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy Recruiting NCT02840175 Phase 3 etanercept;adalimumab;Abatacept;Tocilizumab
7 A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773978 Phase 3 Baricitinib;Placebo
8 A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA) Recruiting NCT03773965 Phase 3 Baricitinib
9 A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Active, not recruiting NCT01844518 Phase 3
10 A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Not yet recruiting NCT03841357 Phase 3 Abatacept Injection
11 A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy Terminated NCT01230827 Phase 3 CNTO 148 (Golimumab);Placebo;Methotrexate
12 A Multicenter, Open Label, Dose Finding Study to Evaluate Efficacy and Safety of Givinostat Administered in Two Different Doses in Patients With Poly JIA Not Adequately Responding to the Standard Treatment. Terminated NCT01261624 Phase 2 Givinostat
13 A Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis Withdrawn NCT01314495 Phase 2 Abatacept;Inactive infusion
14 A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Polyarticular Juvenile Idiopathic Arthritis Completed NCT01904279 Phase 1 Tocilizumab
15 Enbrel-JIA Use Results Survey [All-Case Surveillance] Completed NCT01145352 Etanercept (genetical recombination)
16 Post-Marketing Surveillance of Humira Injection in Korean JIA Patients Under the New-Drug Re-examination Completed NCT02141984
17 Determination of the Effective Individual Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis Completed NCT02030613
18 A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE Active, not recruiting NCT00783510 Methotrexate
19 Patient Centered Adaptive Treatment Strategies for Juvenile Idiopathic Arthritis Using Bayesian Causal Inference Active, not recruiting NCT02524340
20 Start Time Optimization of Biologics in Polyarticular JIA Active, not recruiting NCT02593006
21 Emergency IND for Provision of Tocilizumab No longer available NCT00862758 Tocilizumab
22 An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Polyarticular Course Juvenile Idiopathic Arthritis (Poly JIA) JIA Terminated NCT01557452 Givinostat

Search NIH Clinical Center for Polyarticular Juvenile Idiopathic Arthritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Etanercept
Tocilizumab

Genetic Tests for Polyarticular Juvenile Idiopathic Arthritis

Anatomical Context for Polyarticular Juvenile Idiopathic Arthritis

MalaCards organs/tissues related to Polyarticular Juvenile Idiopathic Arthritis:

41
Bone, T Cells, Neutrophil, B Cells, Whole Blood, Thymus, Endothelial

Publications for Polyarticular Juvenile Idiopathic Arthritis

Articles related to Polyarticular Juvenile Idiopathic Arthritis:

(show top 50) (show all 185)
# Title Authors PMID Year
1
Expanding the spectrum of A20 haploinsufficiency in two Chinese families: cases report. 38
31299923 2019
2
Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis. 38
31308202 2019
3
Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. 38
31359057 2019
4
Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis: A Cross-sectional Analysis of Clinical Features and Medication Use. 38
29781829 2019
5
Questions regarding the relationship between serum levels of S100A8/A9 and S100A12 and the maintenance of clinically inactive disease in JIA: Comment on the article by Claas H. Hinze et al. 38
31233280 2019
6
[Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs]. 38
31087133 2019
7
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. 38
30536638 2019
8
Biallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis. 38
30872671 2019
9
Slow speed resistance exercise training in children with polyarticular juvenile idiopathic arthritis. 38
31191051 2019
10
PAIN PERCEPTION AND PAIN COPING MECHANISMS IN CHILDREN AND ADOLESCENTS WITH JUVENILE FIBROMYALGIA AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. 38
29898009 2019
11
Physical Fitness in Patients with Oligo- and Polyarticular Juvenile Idiopathic Arthritis Diagnosed in the Era of Biologics - A Controlled Cross-Sectional Study. 38
30474929 2018
12
Physical activity in patients with oligo- and polyarticular juvenile idiopathic arthritis diagnosed in the era of biologics: a controlled cross-sectional study. 38
30333025 2018
13
Height and sexual maturation in girls with juvenile idiopathic arthritis. 38
30339783 2018
14
SB5: An Adalimumab Biosimilar. 38
30251234 2018
15
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. 38
30054164 2018
16
Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan. 38
29293033 2018
17
Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. 38
30089725 2018
18
Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. 38
29426059 2018
19
Plasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with co-existing pneumonia. 38
28328098 2018
20
Bilateral absence of the cruciate ligaments with meniscal dysplasia: Unexpected diagnosis in a child with juvenile idiopathic arthritis. 38
29635139 2018
21
High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. 38
29287303 2018
22
Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors. 38
29316374 2018
23
Adiposity in Juvenile Psoriatic Arthritis. 38
29247150 2018
24
Is palindromic rheumatism amongst children a benign disease? 38
29439723 2018
25
The First Report of Multicentric Carpotarsal Osteolysis Syndrome Caused by MAFB Mutation in Asian. 38
30305815 2018
26
Prior to extension, Transcriptomes of fibroblast-like Synoviocytes from extended and Polyarticular juvenile idiopathic arthritis are indistinguishable. 38
29310668 2018
27
Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. 38
29116003 2017
28
Tocilizumab (Actemra). 38
28841363 2017
29
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. 38
28770976 2017
30
Interleukin-33 as a marker of disease activity in rheumatoid factor positive polyarticular juvenile idiopathic arthritis. 38
27785924 2017
31
Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept. 38
28638688 2017
32
Golimumab: A Review in Inflammatory Arthritis. 38
28530020 2017
33
Juvenile Idiopathic Arthritis. 38
28418334 2017
34
Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. 38
28277841 2017
35
No association between vitamin D levels around time of birth and later risk of developing oligo- and polyarticular juvenile idiopathic arthritis: a Danish case-cohort study. 38
27460412 2017
36
Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab. 38
27166661 2017
37
Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis. 38
29168357 2017
38
Pathway analysis based on Monte Carlo Cross-Validation in polyarticular juvenile idiopathic arthritis. 38
27894617 2017
39
Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. 38
27709443 2016
40
Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. 38
27059807 2016
41
Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials. 38
27989499 2016
42
A Novel Method for Pathway Identification Based on Attractor and Crosstalk in Polyarticular Juvenile Idiopathic Arthritis. 38
27804927 2016
43
Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. 38
27881144 2016
44
Multifocal pigmented villonodular synovitis in a child: A case report. 38
27537585 2016
45
Whole blood expression profiling from the TREAT trial: insights for the pathogenesis of polyarticular juvenile idiopathic arthritis. 38
27388672 2016
46
Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor. 38
26474088 2016
47
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). 38
25926155 2016
48
A novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor. 38
26806845 2016
49
Palisaded Neutrophilic Granulomatous Dermatitis in a Child with Juvenile Idiopathic Arthritis on Etanercept. 38
26860064 2016
50
Juvenile arthritis disease activity score is a better reflector of active disease than the disease activity score 28 in adults with polyarticular juvenile idiopathic arthritis. 38
26715652 2016

Variations for Polyarticular Juvenile Idiopathic Arthritis

Expression for Polyarticular Juvenile Idiopathic Arthritis

Search GEO for disease gene expression data for Polyarticular Juvenile Idiopathic Arthritis.

Pathways for Polyarticular Juvenile Idiopathic Arthritis

GO Terms for Polyarticular Juvenile Idiopathic Arthritis

Biological processes related to Polyarticular Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.32 TNF BTK
2 T cell receptor signaling pathway GO:0050852 9.26 HLA-DRB4 BTK
3 response to organic substance GO:0010033 9.16 TNF BTK
4 apoptotic signaling pathway GO:0097190 8.96 TNF BTK
5 I-kappaB kinase/NF-kappaB signaling GO:0007249 8.62 TNF BTK

Sources for Polyarticular Juvenile Idiopathic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....